Why MSB could go back to $2+ in a month

We lose a partner on our lead Tier 1 program... risk & reward profile has changed, analysts are annoyed, general media are negative and shareholders feel let down.

All leading to a approx. 40% written off the value.

What people need to realise is that MSB is not a one trick pony... CHF is not its only Tier 1 program. Putting CHF aside, the real value drivers in the short term were always going to be in the RA and back-pain space. Two areas of significant unmet needs and industry interest.

We are in mid-June 2016 and there is no change to the expectation that Phase 2 RA full trial results will be received in July16. This has been earmarked as a key value inflexion point to potential partners and if the second cohort is in line with the first cohort of RA patients, then we can expect an RA partner to emerge and supply MSB with the non-dilutive cash that it needs to fund its operations beyond the next 9-12 months.

The backbone of MSB is always going to be its technology and there is a clear opportunity for MSB to demonstrate its efficacy in RA within a month.

Behind this there is MSB's back-pain treatment which again has the pain industry very excited.

I believe these will be the focus for MSB in the coming 6 months, and if MSB can secure one or two of these partnerships.. we will not only see it go up to $2, but far far beyond.